XLR8 Medical Research

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Psoriasis8 trials
• Atopic dermatitis (eczema)3 trials
• Hidradenitis suppurativa1 trial

Phase

• Phase 310 trials
• Phase 22 trials

Status

• Active, not recruiting6 trials
• Completed5 trials
• Withdrawn1 trial

Lead sponsor

• Janssen Research & Development, LLC4 trials
• Incyte Corporation3 trials
• Alumis Inc2 trials
• Takeda2 trials
• Bristol-Myers Squibb1 trial

Running trials

• Active, not recruiting

  A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis

  NCT07230860· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

  NCT06846541· Phase 3· Alumis Inc· Source

• Active, not recruiting

  A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

  NCT06550076· Phase 3· Takeda· Source

• Active, not recruiting

  A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

  NCT06220604· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

  NCT06143878· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis

  NCT06095115· Phase 3· Janssen Research & Development, LLC· Source

Closed trials

• Completed

  A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis

  NCT06973291· Phase 3· Takeda· Source

• Completed

  A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001

  NCT06588738· Phase 3· Alumis Inc· Source

• Withdrawn

  Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2

  NCT05233410· Phase 3· Incyte Corporation· Source

• Completed

  Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa

  NCT05635838· Phase 2· Incyte Corporation· Source

• Completed

  Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis

  NCT05456529· Phase 3· Incyte Corporation· Source

• Completed

  Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis

  NCT04036435· Phase 3· Bristol-Myers Squibb· Source